Clincosm LogoSign in Get a demo

DLBCL

Showing 26 - 49 of 49
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma Trial in United States (CYT-0851, CYT-0851 in combination with gemcitabine,

Recruiting
  • Malignancy
  • +14 more
  • Scottsdale, Arizona
  • +17 more
Mar 7, 2022

B-ALL, DLBCL, B ALL Trial in New York (131-I Apamistamab, CAR T-cell)

Recruiting
  • B-ALL
  • +10 more
  • 131-I Apamistamab
  • CAR T-cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 7, 2022

DLBCL Trial in Belgium, France (Tafasitamab, Lenalidomide, Rituximab)

Recruiting
  • DLBCL
  • Brussels, Belgium
  • +14 more
Mar 3, 2022

DLBCL Trial in Seoul (Tislelizumab, Pemetrexed)

Not yet recruiting
  • DLBCL
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Feb 15, 2022

Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL Trial in

Enrolling by invitation
  • Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy
  • +4 more
  • AUTO CAR T cell therapy
  • London, United Kingdom
  • +3 more
Feb 2, 2022

NHL, DLBCL Trial in Belgium, Netherlands (Atezolizumab)

Active, not recruiting
  • NHL
  • DLBCL
  • Antwerpen, Belgium
  • +31 more
Jan 19, 2022

B-ALL, B-cell Non Hodgkin Lymphoma, DLBCL Trial in Stanford (Fludarabine, Cyclophosphamide, CD22 CAR)

Recruiting
  • B-ALL
  • +3 more
  • Stanford, California
    Stanford Medical Center
Jan 14, 2022

DLBCL, Lymphoma, B-Cell Trial in Rochester (Polatuzumab vedotin, Rituximab, Cyclophosphamide)

Recruiting
  • DLBCL
  • Lymphoma, B-Cell
  • Polatuzumab vedotin
  • +4 more
  • Rochester, New York
    University of Rochester
Jan 6, 2022

DLBCL, Neurotoxicity Syndromes Trial in United States (Defibrotide)

Terminated
Has Results
  • DLBCL
  • Neurotoxicity Syndromes
  • Phoenix, Arizona
  • +4 more
Nov 10, 2021

DLBCL Trial in Shanghai (IBI110 plus sintilimab, IBI110)

Not yet recruiting
  • DLBCL
  • Shanghai, Shanghai, China
    Ruijin Hospital affiliated to Shanghai Jiao Tong University Scho
Sep 1, 2021

Lymphoma, DLBCL, Follicular Lymphoma Trial in Belgium, France (Tazemetostat, Rituximab, Cyclophosphamide)

Recruiting
  • Lymphoma
  • +2 more
  • Bruxelles, Belgium
  • +30 more
Jul 23, 2021

DLBCL, Diffuse Large B Cell Lymphoma Trial in Worldwide (R-pola-mini-CHP, R-mini-CHOP)

Recruiting
  • DLBCL
  • Diffuse Large B Cell Lymphoma
  • Aalborg, Denmark
  • +44 more
Jul 8, 2021

DLBCL Trial (R2-CHOP(Lenalidomide,Rituximab,cyclophosphamide,hydroxyldaunorubicin,Vincristine,Prednisone)))

Not yet recruiting
  • DLBCL
  • (no location specified)
Apr 12, 2021

DLBCL, Richter Syndrome Trial in United Kingdom, United States (acalabrutinib, vistusertib)

Terminated
Has Results
  • DLBCL
  • Richter Syndrome
  • Fairway, Kansas
  • +10 more
Jan 4, 2021

DLBCL Trial in Rotterdam (R-DHAP, Brentuximab Vedotin)

Recruiting
  • DLBCL
  • R-DHAP
  • Brentuximab Vedotin
  • Rotterdam, Netherlands
    NL-Rotterdam-ERASMUSMC
Dec 9, 2020

Diet, Physical Activity and Body Composition Changes During

Withdrawn
  • Non-Hodgkin Lymphoma
  • +2 more
  • 24-hour dietary recall
  • +7 more
  • Washington, District of Columbia
    Milken Institute School of Public Health, George Washington Univ
Oct 2, 2020

DLBCL Trial (Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day

Approved for marketing
  • DLBCL
  • Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression
  • (no location specified)
Aug 26, 2020

DLBCL Trial in Belgium, France (RCHOP21)

Completed
  • DLBCL
  • Antwerpen, Belgium
  • +82 more
Jul 10, 2020

SMOLY : Phenotype and Functions of Monocyte Subtypes in High

Completed
  • DLBCL
    • Rennes, Brittany, France
      Rennes Univeristy Hospital
    Nov 5, 2019

    Non-Hodgkin Lymphoma, DLBCL, Diffuse Large B-cell Lymphoma Trial in United States (SGN-CD19B)

    Terminated
    • Non-Hodgkin Lymphoma
    • +3 more
    • Birmingham, Alabama
    • +15 more
    Aug 9, 2018

    Advanced Cancers, DLBCL, Lymphoma Trial in United States (IONIS-STAT3Rx)

    Completed
    • Advanced Cancers
    • +2 more
    • Scottsdale, Arizona
    • +8 more
    Jun 20, 2018

    DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans

    Completed
    • DLBCL
      • Amiens, France
      • +16 more
      Apr 6, 2018

      DLBCL, MCL, Recurrent Disease Trial in Meldola (90Y-DOTATOC)

      Terminated
      • DLBCL
      • +2 more
      • Meldola, FC, Italy
        Nuclear Medicin Division, IRST IRCCS
      Mar 16, 2018

      DLBCL Trial in Hwasun-gun (Intrathecal methotrexate, High-dose intravenous methotrexate)

      Unknown status
      • DLBCL
      • Intrathecal methotrexate
      • High-dose intravenous methotrexate
      • Hwasun-gun, Jeollanam-do, Korea, Republic of
        Chonnam National University Hwasun Hospital
      Apr 21, 2017